Trials / Completed
CompletedNCT02219516
Mild, Moderate and Severe Renal Impairment Study
A Phase 1, Single-Dose, Open Label, Pharmacokinetic and Pharmacodynamic Study of RDEA3170 in Adult Male Subjects With Mild, Moderate, and Severe Renal Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Ardea Biosciences, Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, single-dose, open-label, pharmacokinetic (PK) and pharmacodynamic (PD) study of RDEA3170 in adult male subjects with mild, moderate, and severe renal impairment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RDEA3170 |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2015-10-30
- Completion
- 2016-05-13
- First posted
- 2014-08-19
- Last updated
- 2017-04-25
- Results posted
- 2017-04-25
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02219516. Inclusion in this directory is not an endorsement.